SCM
Sio Capital Management Portfolio holdings
AUM
$249M
This Quarter Return
+10.46%
1 Year Return
+117.71%
3 Year Return
+238.99%
5 Year Return
+411.91%
10 Year Return
+912.87%
AUM
$223M
AUM Growth
+$223M
(-16%)
Cap. Flow
-$64.4M
Cap. Flow
% of AUM
-28.85%
Top 10 Holdings %
Top 10 Hldgs %
67.81%
Holding
57
New
8
Increased
3
Reduced
13
Closed
16
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$24.3M |
| 2 |
Maximus
MMS
|
$14.5M |
| 3 |
Annexon
ANNX
|
$8.48M |
| 4 |
Relay Therapeutics
RLAY
|
$6.7M |
| 5 |
CMPS
Compass Pathways
CMPS
|
$3.91M |
Top Sells
| 1 |
Teleflex
TFX
|
$17.8M |
| 2 |
Labcorp
LH
|
$16.2M |
| 3 |
Smith & Nephew
SNN
|
$14.4M |
| 4 |
Organon & Co
OGN
|
$12.6M |
| 5 |
GSK
GSK
|
$12M |
Sector Composition
| 1 | Healthcare | 88.55% |
| 2 | Industrials | 6.48% |
| 3 | Consumer Staples | 4.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Labcorp
LH
$23.1B
| $38.7M | 15.36% | 173,293 -72,609 | -30% | -$16.2M |
|
|
2
Teva Pharmaceuticals
TEVA
$21.1B
| $24.3M | 9.64% | +1,349,274 | New | +$24.3M |
|
|
3
Maximus
MMS
$4.95B
| $14.5M | 5.73% | +155,142 | New | +$14.5M |
|
4
Zimmer Biomet
ZBH
$21B
| $13.8M | 5.46% | 127,511 -27,793 | -18% | -$3M |
|
|
VXRT
5
DELISTED
Vaxart
VXRT
| $11.6M | 4.58% | 13,608,244 -1,156,747 | -8% | -$982K |
|
6
Kenvue
KVUE
$39.7B
| $11M | 4.35% | 474,741 -10,259 | -2% | -$237K |
|
|
7
Teleflex
TFX
$5.59B
| $9.71M | 3.85% | 39,272 -71,806 | -65% | -$17.8M |
|
8
Tyra Biosciences
TYRA
$675M
| $9.42M | 3.74% | 400,870 -199,424 | -33% | -$4.69M |
|
9
Disc Medicine
IRON
$2.07B
| $9.24M | 3.66% | 187,941 -4,059 | -2% | -$199K |
|
10
Cigna
CI
$80.3B
| $9.18M | 3.64% | 26,503 -283 | -1% | -$98K |
|
|
11
Annexon
ANNX
$226M
| $8.48M | 3.36% | +1,433,155 | New | +$8.48M |
|
12
Biodesix
BDSX
$62.6M
| $7.72M | 3.06% | 4,338,514 -9,341 | -0.2% | -$16.6K |
|
|
13
Relay Therapeutics
RLAY
$619M
| $6.7M | 2.66% | +945,839 | New | +$6.7M |
|
14
Erasca
ERAS
$445M
| $6.06M | 2.4% | 2,219,186 -655,350 | -23% | -$1.79M |
|
|
CMPS
15
Compass Pathways
CMPS
$424M
| $5.76M | 2.29% | 914,639 +621,222 | +212% | +$3.91M |
|
16
Astria Therapeutics
ATXS
$349M
| $5.56M | 2.2% | 504,887 -5,380 | -1% | -$59.2K |
|
17
PMV Pharmaceuticals
PMVP
$74.2M
| $4.79M | 1.9% | 3,214,239 +505,831 | +19% | +$754K |
|
18
Ventyx Biosciences
VTYX
$171M
| $4.3M | 1.7% | 1,971,948 +1,193,024 | +153% | +$2.6M |
|
19
IDEAYA Biosciences
IDYA
$2.15B
| $3.9M | 1.55% | +123,000 | New | +$3.9M |
|
20
Artivion
AORT
$2.07B
| $3.23M | 1.28% | +121,178 | New | +$3.23M |
|
|
CRGX
21
DELISTED
CARGO Therapeutics
CRGX
| $3.21M | 1.27% | +173,860 | New | +$3.21M |
|
22
Context Therapeutics
CNTX
$75.4M
| $2.6M | 1.03% | 1,328,352 | – | – |
|
23
Enanta Pharmaceuticals
ENTA
$180M
| $1.83M | 0.73% | 177,004 | – | – |
|
24
Nuvation Bio
NUVB
$1.02B
| $1.53M | 0.61% | 668,115 | – | – |
|
25
Foghorn Therapeutics
FHTX
$286M
| $1.13M | 0.45% | 121,672 | – | – |
|